The Btk inhibitor, ibrutinib (Imbruvica, Pharmacyclics), was approved by the US FDA in November 2013 for treating mantle cell lymphomas [19] and presented encouraging clinical efficacy and tolerability profiles in patients with relapsed chronic lymphocytic leukemia/small lymphocytic lymphomas [20]. Here, BTK is linked to B-cell chronic lymphocytic leukemia.